Altimmune (ALT) Other Non-Current Liabilities (2010 - 2026)

Altimmune (ALT) has 17 years of Other Non-Current Liabilities data on file, last reported at $5.8 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $5.8 million, up 36243.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.8 million (up 36243.75% YoY), and the FY2025 annual result was $5.8 million, up 7.94% from the prior year.
• Other Non-Current Liabilities advanced to $5.8 million in Q1 2026 per ALT's latest filing, from $5.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $5.8 million in Q1 2026 and troughed at $16000.0 in Q1 2025.
• A 5-year average of $2.7 million and a median of $2.2 million in 2022 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2026: Other Non-Current Liabilities slumped 99.01% in 2022, then surged 36243.75% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $60000.0 in 2022, then tumbled by 33.33% to $40000.0 in 2023, then soared by 13225.0% to $5.3 million in 2024, then rose by 7.94% to $5.8 million in 2025, then climbed by 1.08% to $5.8 million in 2026.
• Business Quant data shows ALT's Other Non-Current Liabilities at $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $5.8 million in Q3 2025.